Seroquel XR in Schizophrenia Relapse Prevention

NCT00990626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2010-11-17

No results posted yet for this study

Summary

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Conditions

  • Schizophrenia Relapse Prevention

Sponsors & Collaborators

Principal Investigators

  • Attila Németh · National Psychiatric Centre

  • Lilla Szabó · AstraZeneca Hungary MC

  • Tamás Bábel · AstraZeneca Hungary MC

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990626 on ClinicalTrials.gov